The Phase I RELEASE Clinical Trial to Evaluate the Safety of NK Cells in COVID-19

The severity of COVID 19 symptoms has a direct correlation with lymphopenia, affecting natural killer (NK) cells. SARS-CoV-2 specific "memory" NK cells obtained from convalescent donors can be used as cell immunotherapy. In 2022 a phase I, dose-escalation, single center clinical trial was conducted to evaluate the safety and feasibility of the infusion of CD3/CD56 NK cells against moderate/severe cases of COVID-19 (NCT04578210). Six participants with pneumonia and/or lymphopenia were infused. Four patients received a single-dose infusion of NK cells of 1×10/kg, and the following two patients a dose of 2×10/kg of NK cells. All participants' clinical status and inflammation markers were monitored. No serious adverse events were reported after infusion. Exploratory outcomes included the donor chimerism, NK-cell immunophenotype evolution, and immune lymphocyte reconstitution. This study provides preliminary evidence supporting the idea that treatment of COVID-19 patients with moderate/severe symptoms using NK from COVID-19 convalescent donors is feasible and safe.

References

Bjorkstrom N, Strunz B, Ljunggren H . Natural killer cells in antiviral immunity. Nat Rev Immunol. 2021; 22(2):112-123. PMC: 8194386. DOI: 10.1038/s41577-021-00558-3. View

Pegram H, Ritchie D, Smyth M, Wiernik A, Prince H, Darcy P . Alloreactive natural killer cells in hematopoietic stem cell transplantation. Leuk Res. 2010; 35(1):14-21. DOI: 10.1016/j.leukres.2010.07.030. View

Tregoning J, Flight K, Higham S, Wang Z, Pierce B . Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021; 21(10):626-636. PMC: 8351583. DOI: 10.1038/s41577-021-00592-1. View

Laforge M, Elbim C, Frere C, Hemadi M, Massaad C, Nuss P . Tissue damage from neutrophil-induced oxidative stress in COVID-19. Nat Rev Immunol. 2020; 20(9):515-516. PMC: 7388427. DOI: 10.1038/s41577-020-0407-1. View

Ghasemzadeh M, Hosseini E, Schwarer A, Pourfathollah A . NK cell maturation to CD56(dim) subset associated with high levels of NCRs overrides the inhibitory effect of NKG2A and recovers impaired NK cell cytolytic potential after allogeneic hematopoietic stem cell transplantation. Leuk Res. 2016; 43:58-65. DOI: 10.1016/j.leukres.2015.12.002. View

Liu W, Kampouri E, Bui J, Sekhon M, Tercero A, Finlay D . Off-the-shelf allogeneic natural killer cells for the treatment of COVID-19. Mol Ther Methods Clin Dev. 2024; 32(4):101361. PMC: 11609367. DOI: 10.1016/j.omtm.2024.101361. View

Ferreras C, Pascual-Miguel B, Mestre-Duran C, Navarro-Zapata A, Clares-Villa L, Martin-Cortazar C . SARS-CoV-2-Specific Memory T Lymphocytes From COVID-19 Convalescent Donors: Identification, Biobanking, and Large-Scale Production for Adoptive Cell Therapy. Front Cell Dev Biol. 2021; 9:620730. PMC: 7947351. DOI: 10.3389/fcell.2021.620730. View

Molfetta R, Quatrini L, Santoni A, Paolini R . Regulation of NKG2D-Dependent NK Cell Functions: The Yin and the Yang of Receptor Endocytosis. Int J Mol Sci. 2017; 18(8). PMC: 5578067. DOI: 10.3390/ijms18081677. View

Ferreras C, Hernandez-Blanco C, Martin-Quiros A, Al-Akioui-Sanz K, Mora-Rillo M, Ibanez F . Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and/or lymphopenia (RELEASE NCT04578210). Cytotherapy. 2023; 26(1):25-35. DOI: 10.1016/j.jcyt.2023.10.002. View

10.

Pituch-Noworolska A . NK cells in SARS-CoV-2 infection. Cent Eur J Immunol. 2022; 47(1):95-101. PMC: 9115590. DOI: 10.5114/ceji.2022.113078. View

11.

Perez-Martinez A, Fernandez L, Valentin J, Martinez-Romera I, Corral M, Ramirez M . A phase I/II trial of interleukin-15--stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors. Cytotherapy. 2015; 17(11):1594-603. DOI: 10.1016/j.jcyt.2015.07.011. View

12.

Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T . Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood. 2007; 110(1):433-40. PMC: 1896125. DOI: 10.1182/blood-2006-07-038687. View

13.

Shu Z, Heimfeld S, Gao D . Hematopoietic SCT with cryopreserved grafts: adverse reactions after transplantation and cryoprotectant removal before infusion. Bone Marrow Transplant. 2013; 49(4):469-76. PMC: 4420483. DOI: 10.1038/bmt.2013.152. View

14.

Sanz J, Gomez Lahoz A, Martin R . [Role of the immune system in SARS-CoV-2 infection: immunopathology of COVID-19]. Medicine (Madr). 2021; 13(33):1917-1931. PMC: 8158328. DOI: 10.1016/j.med.2021.05.005. View

15.

Ghasemzadeh M, Ghasemzadeh A, Hosseini E . Exhausted NK cells and cytokine storms in COVID-19: Whether NK cell therapy could be a therapeutic choice. Hum Immunol. 2021; 83(1):86-98. PMC: 8423992. DOI: 10.1016/j.humimm.2021.09.004. View

16.

Churpek M, Snyder A, Han X, Sokol S, Pettit N, Howell M . Quick Sepsis-related Organ Failure Assessment, Systemic Inflammatory Response Syndrome, and Early Warning Scores for Detecting Clinical Deterioration in Infected Patients outside the Intensive Care Unit. Am J Respir Crit Care Med. 2016; 195(7):906-911. PMC: 5387705. DOI: 10.1164/rccm.201604-0854OC. View

17.

Gasior M, Ferreras C, de Paz R, Bueno D, Mozo Y, Sisinni L . The role of early natural killer cell adoptive infusion before engraftment in protecting against human herpesvirus-6B encephalitis after naïve T-cell-depleted allogeneic stem cell transplantation. Transfusion. 2021; 61(5):1505-1517. DOI: 10.1111/trf.16354. View

18.

Muscari I, Fierabracci A, Adorisio S, Moretti M, Cannarile L, Thi Minh Hong V . Glucocorticoids and natural killer cells: A suppressive relationship. Biochem Pharmacol. 2022; 198:114930. DOI: 10.1016/j.bcp.2022.114930. View

19.

Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang Y . Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020; 5(1):33. PMC: 7100419. DOI: 10.1038/s41392-020-0148-4. View

20.

Gleason J, Zhao Y, Raitman I, Kang L, He S, Hariri R . Human placental hematopoietic stem cell derived natural killer cells (CYNK-001) mediate protection against influenza a viral infection. Hum Vaccin Immunother. 2022; 18(5):2055945. PMC: 9255201. DOI: 10.1080/21645515.2022.2055945. View